Dianthus Therapeutics, Inc. /DE/ (DNTH) Financials
Annual revenue, profitability and per-share results for Dianthus Therapeutics, Inc. /DE/, as reported in SEC filings.
Revenue • FY2025
$2.04M
▼ 67.3%YoY
Net income • FY2025
-$162.34M
▼ 91.1%YoY
Diluted EPS • FY2025
-$4.20
▼ 64.7%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.04M | -$162.34M | — | -$4.20 | -$129.27M | -8739.3% | -67.3% |
| FY2024 | $6.24M | -$84.97M | — | -$2.55 | -$78.28M | -1633.7% | +120.6% |
| FY2023 | $2.83M | -$43.55M | — | -$8.45 | -$36.97M | -1704.7% | — |
| FY2022 | — | -$28.48M | — | -$32.57 | -$29.21M | — | — |
Figures as reported in Dianthus Therapeutics, Inc. /DE/'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a DNTH filing.
Get an email when DNTH files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.